Opportunities, risks and challenges in global mental health and population neuroscience: a case of Sino-German cooperation

Shuyan Liu1 · Sabine Müller1 · Raymond J. Dolan2 · Xudong Zhao3 · Jialin C. Zheng4,5,6,7 · Andreas Heinz1

Received: 23 March 2020 / Accepted: 22 July 2020 / Published online: 29 July 2020
© The Author(s) 2020

Abstract
Large scale prospective cohorts have now been established across several countries, and continents, and among the aims include an assessment of the developmental trajectory of mental disorders. This level of international cooperation helps transfer research findings to new social contexts as well as enabling an assessment of which findings can be replicated, and which interventions are most effective, in different social and cultural settings. However, data sharing across different regional and national health care systems requires a careful consideration of different standards in ethical research, data protection and patient care, including respect for patients’ rights, in cooperating jurisdictions. In our review, we discuss ethical, legal and practical challenges associated with such cooperation with a focus on research participants, specifically patient recruitment, by considering the instance of China and Germany. Our broader aim is to promote international cooperation by identifying key challenges that arise in international cooperation, and to facilitate an exchange in relation to legal and practical approaches.

Keywords Large-scale cohort studies · Ethics · Data security and privacy · Laws and regulations · Patient care · Population neuroscience

Introduction
Large-scale, long-term, prospective cohort studies are invaluable in fostering a deeper understanding of the relative contributions and potential interactions of environmental factors and genetic predisposition, including epigenetic mechanisms underlying psychiatric disorders. These questions can be addressed powerfully through population neuroscience [30]. The IMAGEN study (https://image-europe.com, an often cited example [40], dates from 2007 and represents the first multisite genetic-neuroimaging study of individual variability in trait impulsivity, reinforcement sensitivity and emotional reactivity that aims to characterize comprehensively the full spectrum of psychiatric disorders. Over more than a decade, the study has recruited over 2000 adolescents (14 years of age), with longitudinal follow-ups at ages 16, 19 and 22 involving acquisition of psychometric tests, neuroimaging and other biomarkers [34]. Neuroimaging data has been acquired at eight sites in the UK, Ireland, France and Germany [40]. Apart from the well-known Neuro Science in Psychiatry Network (NSPN) study from the University of Cambridge and University College London (https://www.nspn.org.uk, [23], the IMAGEN study is the only published large-scale
cohort that includes both structural and functional magnetic resonance imaging dataset of subjects from the beginning of adolescence through into young adulthood [40]. A series of prospective cohort studies have subsequently been developed in other continents as part of the so-called Global Imaging Genetics Initiative in Adolescence (GIGA, involving collaborators in the United States, India, UK, Europe and China, that aim to ascertain impact of environment, ethnicity, culture and society on mental health [39]. In addition to standard metrics, GIGA assesses environmental factors using mobile-based technology with collection of real-time data whilst an analysis of satellite data, once set up, can be used to index features of urbanization over time and across geographical regions.

Systematic comparison of data across sites has the potential to identify biomarkers relevant to global mental health. Prospective cohort studies avail of ambulatory assessments for experience sampling as well as the mapping of environmental risk factors in everyday life [17]. This provides a unique opportunity to assess cultural and regional differences in social and environmental factors (e.g., stress exposure, failures in the caregiving environment, and substance use) pertaining to mental health [17]. Concerted international efforts are in train to streamline and harmonize these cohorts, at least with regards to studies on the clinical and psychometric characteristics of patients, as well as structural and functional neuroimaging techniques and procedures [39].

However, there are significant potential pitfalls arising out of such cross-border jurisdiction and cross-cultural enterprises although ethical standards are established by international conventions like the Declaration of Helsinki of the World Medical Association [3], the ethical guidelines of the Council for International Organisations of Medical Sciences [29], the Convention of Biomedicine of the European Council [7]. These pitfalls have not been clearly addressed in the literature, and they are the primary focus of this review.

First and foremost, there is a concern regarding data security and privacy, particularly with respect to ambulatory assessments, where these may include geolocation and information relating to behaviours such as substance and illicit drug use. Secondly, ethical requirements for research vary considerably across countries and this variability poses a challenge when conducting international studies. Finally, there is a concern that as soon as patients with mental health problems are involved in clinic research, patients within institutional care settings in in particular may feel undue pressure to participate in research, or harbour unfounded fears that findings emerging from study participation might negatively affect their status. We address these questions by considering cooperation with Chinese scientists regarding a planned establishment of a “Sino-German Mental Health Centre”.

### The pitfalls of international cooperation

#### Ethics committees and review boards in Germany and China

Research ethics committees (Institutional Review Board, IRB) are required by all international ethical standards governing research involving human participants, as well as by local law in many jurisdictions. They are responsible for ensuring the protection of rights, safety and well-being of participants involved in clinical research. Unsurprisingly, considerable variation exists between ethics committees of different countries, which is a challenge for researchers wishing to conduct international studies, particularly when local ethical norms of one country are inconsistent with espoused universal ethical principles [25].

In Germany, all human subject research is required by law to acquire full ethical approval [12]. Ethics committee members in Germany come from a variety of academic backgrounds, which includes lay members and an appropriate gender balance. Thus, according to Article 41 of the German Medicinal Product Act (“Arzneimittelgesetz”, AMG), ethics committees should be constituted to include a balanced gender ratio (https://www.jusline.at/gesetz/amg/paragraf/41). According to the EU Clinical Trials Regulation from 2014, a lay member or patient representative has to be member of each research ethics committee. In Germany, committees are mandated to scrutinise the potential benefits for patients as well as the importance of the proposed research, weighing these considerations up against risks and burdens for participants. To perform an adequate risk/benefit assessment, committee members in Germany do not base their assessment solely on information provided in a protocol, but also actively seek out additional information, consult experts and exchange information with other committees. In the case of a large-scaled multisite cohort study in Germany, a local ethics committee may approve research after an affirmative recommendation has been received from a lead site, where the proposal was initially evaluated. For example, the multisite IMAGEN study was approved by a local research ethics committee at each national site in depth and then reviewed further by data protection officers at each site.

For China, it has been questioned whether scientists adhere to high ethical standards compared, for example, to those in Europe [55]. In fact, both the National Natural Science Foundation of China and Chinese Academy of Sciences have long established detailed regulations and guidelines [55]. Different types of institutions and authorities in China vary in the composition of their research ethics committees as to number, gender and professional
background, and the statutory body [50]. Regarding the gender balance of ethics committee members, it was required in Chinese regulatory documents “Guiding Principles of Ethical Review of Drug Clinical Trials” and “Norms on the Quality Management for the Clinical Trials of Medical Devices” issued by the State Food and Drug Administration in 2010 and in 2016 respectively, while most regulatory documents issued by China’s relevant authorities did not mention it [50]. China’s National Health and Family Planning Commission issued one of the most detailed provisions in “Measures for the Ethical Reviews of Biomedical Research Involving Humans (2016)” [50]. It stipulates that ethics committee members of medical and health institutions should be chosen from different fields including biomedicine, ethics, jurisprudence, sociology and the general public and should consist of no less than seven people, with lay members as optional [50]. In Shanghai, in 2008 52% of 33 public hospitals had engaged lay members for their ethics committees [53]. However, these rules are not always rigorously executed across the entire country. Many research institutions in China have not established objective and reliable mechanisms to deal with ethical issues and are often reluctant to deliver a definitive verdict on misconduct cases or impose appropriate punitive measures when there are violations [55]. This institutional tolerance and the system that evaluates a researcher mainly by the number of publications in both Germany and China, is a potential contributor to research misconduct [11, 33].

Ambulatory assessments with apps that provide geolocation as well as brain-inspired artificial intelligence is revolutionizing neuroscience, and this raises serious ethical concerns such that international consensus needs to be reached to take account of the unique characteristics of individual participating countries [15]. It is gratifying that both German and Chinese governments have provided explicit support for neuroethics research. An example is the German Federal Ministry of Education and Research (BMBF), together with European Research Area Networks fund joint transnational projects on Ethical, Legal, and Social Aspects (ELSA) of Neuroscience (https://www.neuron-eranet.eu). In China, there is an ongoing project [48] aiming at evaluating ethical issues related to the convergence of nanotechnology, biomedicine, information technology, and cognitive science (NBIC) [37] to ameliorate human capabilities [10, 47]. The ethical issues of this project are especially relevant for cognitive neuroscience research following the launch of the China Brain Project [32], which has clear priority objectives for integrating an ethical framework, addressing relevant ethical concerns, and planning for solutions [32].

As cultural factors can influence the extent and pace at which each society adapts to the international ethical guidelines, the International Brain Initiative (https://www.internationalbraininitiative.org) has been established to coordinate efforts across existing and emerging national and regional brain research initiatives. In this context, Global Neuroethics Summit Delegates have listed key ethical questions to guide ethical research [2].

Data privacy, data security and compliance risk

Personal data privacy protection is a fundamental human right, and therefore it must be rigorously guaranteed by the research community. Many recent examples of unethical research practices have involved unauthorised collection and/or (mis)use of personal data, resulting in enforcement action by regulators [44]. In the European Union (EU), all research projects need to stay compliant with the General Data Protection Regulation 2016/679 (GDPR). Personal data must be processed in compliance with the EU and national data protection laws. Thus, research proposals that involve personal data must also comply with relevant ethical-legal principles. In light of the GDPR, some institutions in Germany have appointed a data protection officer to be involved in all stages of a project regarding data privacy issues. At these institutions (e.g., Charité–Universitätsmedizin Berlin), the ethics committees require separate project reports from this local data protection officer on all human studies in relation to a potential violation of data protection regulations. This extends to providing a complete list of internet service providers involved in handling data, users of such databases, adherence to pseudonymisation and anonymisation and time limits for erasure or review of stored data. However, surprisingly some institutions do not have a data protection officer. In this case, instead of specifically requiring external review, ethics committees at these institutions (e.g., Technical University of Dresden and Central Institute of Mental Health in Mannheim) have at least some member who has basic competence in data protection. With GDPR entering into force in 2018, the stage is set for international debate on Big Data sharing and international data transfers. Where complex, sensitive or large-scale data processing is envisaged or data are to be transferred outside the EU, consultation with the data protection officer is required regarding compatibility in data protection arrangements with respect to the host institution’s policies and relevant applicable legislation.

Furthermore, the right to the protection of personal data is enshrined in the Article eight under the Charter of Fundamental Rights of the EU, where each individual has the right to be informed about the collection and use of their personal data. For research, the EU has published a document on ethics and data protection in 2018 (https://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/ethics/h2020_hi_ethics-data-protection_en.pdf). It prescribes that in research settings, data protection imposes obligations on researchers to provide
research subjects with detailed information about what will happen to personal data collected. It also requires the organisations processing the data to ensure that the data are properly protected, minimised, and destroyed when no longer needed.

China’s data privacy framework is splintered across rules enshrined in more than 200 laws, measures and sector-specific regulations. The Cyber Security Law, effective from 1 June 2017, provides for the first time a framework for comprehensive regulations of data protection in the form of national-level legislation. However, it does not spell out clearly the key requirements involving consent, anonymization, and securing personal information, and these questions were not addressed until 2018. In March 2018, China’s National Information Security Standardization Technical Committee (TC260) issued a recommended national standard ("GuoBiao/Tuijian", GB/T), the Personal Information Security Specification GB/T 35,273–2017 (PIS Specification) [31]. Like the GDPR, China’s PIS Specification includes guidance on user consent, data protection, data access, the obligation of disclosure, and the evaluation of data security, but overall it is more permissive. For instance, Article six of the GDPR sets out six conditions (user consent, contract, legal obligation, vital interests, public task and legitimate interests) and at least one of these must apply in which personal data processing is legally permitted (https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1528874672298&uri=CELEX:02016R0679-20160504).

In China, the PIS Specification only lists four types of personal data (basic personal information, personal identity information, personal health and biometric information, personal education and work information) which data controllers are not allowed to process (https://www.datalaw.io/index.php/2019/08/05/the-right-of-access-of-access-to-personal-data-in-the-largest-global-internet-digital-marke ts/). Also, the PIS Specification is not mandatory, but only a recommended standard that cannot give Chinese citizens any rights to protect their privacy [31]. This is quite different from a Western notion of data privacy: China’s legislation on personal information protection may consider balancing business, government, society and science interests and calls for the importance of establishing the right to privacy. Nevertheless, China has made strides with regards to data protection, inspired by worldwide expertise and experience [48]. Recognizing the necessity to enhance patient safety and standardization of clinical trials regulation, the China Food and Drug Administration strengthened the encryption of patient information and emphasized that comprehensive informed consent is a prerequisite for clinical trials in its recently published amendment to laws and regulations on clinical trials of medicine and medical devices, in 2017 (https://english.nmpa.gov.cn/2019-12/16/c_432394.htm).

Inadequate treatment and poor patient care

A key obstacle to ethically informed research on patients with mental disorders is undue pressure that is imposed on patients to consent to study participation, particularly within institutional settings. On the other hand, a current focus on patient-centred approaches to research and treatment allows patients to get involved in making their own decisions [19]. However, this approach is not always safeguarded in clinical practice and research. There are still only exceptional examples of efforts to engage patients in planning and discussing of mental health research [38]. In order to achieve more active patient participation in international research process, there is a need to improve the level of information that patients and society as a whole have on research objectives and processes. The goal here is to promote and measure the impact of patient participation in research and healthcare and to reduce undue pressure on patients to participate in studies.

In Germany, the National Association of Psychiatrists and Psychotherapists, DGPPN, has a so-called Trialogue Board that includes representatives of the major organizations of patients and relatives, who discuss national mental health care practices and policies together with professionals. There are also increasing opportunities for patients to participate more actively in the entire research process. For example, in a Collaborative Research Centre (TRR 265) in Germany (https://sfb-trr265.charite.de/en/), a stakeholder board was established that includes representatives of organisations of patients and relatives as well as public health care. In China, mental health policy implementation at local level do not capture the views or knowledge of all key stakeholders [54]. There is a great need to involve stakeholders including mental health professionals, parents, social services, religious leaders, and educators [54].

In spite of these efforts, a persisting lack of patient involvement in clinical research is the norm in many countries. This might, in part, be explicable by differences in the relative emphasis assigned to ethical principles (respect for autonomy, beneficence, non-maleficence, and justice) guiding the doctor-patient relationship [38, 48]. The traditional relational model, based on a principle of beneficence, which in turn is based on the authority of the doctor, may contribute to the fact that research is often performed for patients, but not with them. Therapeutic misconceptions, the absence of patients in many Institutional Review Boards (IRBs), poor quality of information provided to participants, and a low level of patient participation in establishing research priorities and study design are all elements highlighting how a beneficence principle predominates in respective national or local research fields [38]. In many countries and settings, doctor-patient relationships are changing, and concepts such as shared decision making, and patient empowerment are
Health Law was enacted in 2012 [5]. This law guarantees, to care for themselves [56]. In China, a national Mental covers non-acute care especially for those who are unable cases [14]. The German guardianship law (Civil Code) regulate admission and compulsory treatment for acute laws in each of the German federal states (Bundesländer) psychiatric hospitals and compulsory treatments. Different laws that apply in each of the 16 German federal states [56]. The German guardianship law (Civil Code) covers non-acute care especially for those who are unable to care for themselves [56]. In China, a national Mental Health Law was enacted in 2012 [5]. This law guarantees, for the first time in China, the right to adequate treatment and provides legal protection in cases of malpractice [51]. The law requires informed consent from all mentally ill patients before they receive inpatient treatment and prohibits involuntary admissions unless those severely ill patients are deemed to have the potential to harm themselves or others [5]. Nevertheless, clinical practice differs widely [24]. The process of drafting, adopting and implementing such legislation provided an opportunity for raising public awareness and educating policy makers and society in general [51].

As local applications and implementations vary in both Germany and China, checking national regulations is not enough to safeguard patients’ rights. Therefore, we now discuss some differences in the clinical practice which are relevant for research in the following sections. A hidden pressure on patients to consent to participate in research can in particular be seen in patients who face long-term involuntary admission or feel the informal pressure to stay in hospital [49]. The duration of treatment varies substantially between countries [9, 41]. In Germany, most psychiatric hospitals offer support for a rather short period of time of usually up to, at most, several months, with the average length of stay being 23.8 days in 2017, according to Federal Statistical Office in 2018 (Data retrieved from the document on page 26, https://www.destatis.de/DE/Themes/Gesellschaft-Umwelt/Gesundheit/Krankenhaeuser/Publikationen/Downlaods-Krankenhaeuser/grunddaten-krankenhaeuser-2120611177004.pdf;jsessionid=278997CAFAE3BE0C49EC28BC1C3D8E6.internet741?__blob=publicationFile). In addition, psychiatric hospitals often provide an integrated outpatient clinic, which facilitates early discharge from inpatient treatment. Furthermore, Germany offers patients partial inpatient treatment (Tagesklinik) to ease a transition from clinic to home. In these settings, patients spend the entire day at the clinic, but go about their everyday lives afterward and sleep at home.

In China, patients usually have a considerably longer stay in psychiatric hospitals. Statistics from 2013 to 2016 showed that inpatients in China spent an average of 240.2 days in specialized hospitals and 95.5 days in community health centres [41]. Many patients have to stay in the closed ward of a psychiatric hospital for a very long time because they either do not dare to leave or because their families are not willing to take them home [52]. Thus, there is urgent need to improve the spirit of humanistic care in mental health services [52], which could also improve the conditions for giving informed consent to study participation.

Furthermore, mental health services in China often suffer from severe understaffing and a scarcity of mental health facilities. Compared to the large population of China, the number of psychiatrists and nurses is exceedingly small. As of 2018, China’s National Health Commission reported there are only 40,435 registered psychiatrists and 101,282 registered psychiatric nurses; that is 2.9 psychiatrists and 7.3 psychiatric nurses per 100,000 population (Data retrieved from the website https://www.xinhuanet.com/health/2019-11/25/c_1125270551.htm). These numbers are much smaller than those in high-income countries with 12.7 psychiatrists and 23.5 psychiatric nurses per 100,000 population according to the Mental Health ATLAS 2017—World Health Organisation (Data retrieved from Fig. 3.2.4 and 3.2.5; https://apps.who.int/iris/bitstream/handle/10665/272735/9789241514019-eng.pdf?ua=1). Meanwhile, there are few social workers and psychotherapists in medical institutions, and the clinicians have nearly no time to communicate with patients and their families [52]. Moreover, psychiatric hospitals are generally poorly equipped and overcrowded compared to other medical facilities in China. Nearly 40 years ago, Allodi and Dukuszta [1] reported that the Shanghai Psychiatric Hospital had 1,006 inpatients beds and 14 wards with an average of approximately 72 patients per ward. In 2019, a psychiatric hospital in Pudong New Area had an average of
approximately 120 patients per ward. One important factor contributing to this insufficiency might be the low salary of mental health clinicians [52]. The per capita incomes of psychiatrists and psychiatric nurses are lower than those of their colleagues in other specialties at general hospitals, such as physicians and surgeons [52]. In China, there is an urgent need to expand the number of psychiatrists and related practitioners, and ensure quality in remuneration with respect to other specialties [52].

Moreover, ward settings can contribute to patient pressure on participating in a clinical study. In many countries, locked entrance doors in psychiatric wards are encountered even by voluntarily admitted patients [13, 36], and can be experienced as forced confinement, an unwanted dependence on staff and lead to emotional distress [16]. In China, most inpatient wards are permanently locked, even though many patients are not legally obliged to stay in the hospital [51]. Recently, some specialist wards in China have changed from completely closed type to more open wards, thus to better meet needs of the patients [42].

In Germany, legally admitted patients are traditionally admitted to locked wards [22], which regularly takes care of patients who voluntarily enter the hospital [6, 20]. However, in recent years, several clinicians and bodies advocate greater efforts towards implementing open door policies in psychiatry, which means treating legally committed patients on open, rather than locked, wards [4, 8]. While concerns have been voiced regarding a potential decrease in security and control [43, 45], several studies suggest that the risk of absconding or violent interactions is not increased in such settings [6, 20, 21]. Future studies should assess whether wards settings (open versus closed) or duration of hospital treatment affect patients’ autonomy when deciding whether to participate in a study offered by the same institution in which they are treated as inpatients.

Conclusion

A population neuroscience perspective emphasizes a need to understand the evolution of human behaviour and the expression of mental well-being across multiple levels of research. There is now an increasing reliance on the use of large cohorts, including ambulatory assessments that monitor many daily life behaviours. These instruments are capable of generating powerful data of scientific value. However, specific types of data sets, such as those that use geolocation data, may intrude upon individuals’ privacy and influence their social interactions. Therefore, safeguards are needed to maintain participants’ autonomy and safeguard their privacy. Research cooperation across jurisdictions should start by reflecting on potential legal and ethical implications of international cooperation. We emphasize the need to ensure the continuing competence of international cooperation through setting an equivalence of baseline standards in legislation relevant to ethics of patient care across countries. We highlight that ethics and data protection measures vary considerably between Germany and China, and we surmise may do so across other continents. Furthermore, ethical frameworks that impinge on research practice differ considerably even across institutions within a jurisdiction, with studies indicating rules are not rigorously executed with equanimity across China [55]. With the advent of GDPR, the EU has established a uniform framework for data protection legislation, and it is notable that there are no equivalent data privacy laws in China. Likewise, ward settings and durations of voluntary and involuntary treatment differ widely between Germany and China [6, 18, 26–28, 48, 51], and there is a striking lack of empirical research in both jurisdictions that assesses the differential impact of inpatient treatment on patients’ autonomy, and their participation in research.

The Department of Psychiatry and Psychotherapy at the Charité Campus Mitte plans to establish a “Sino-German Mental Health Centre” together with Tongji University School of Medicine in Shanghai. The proposed centre will address an urgent need for independent replication in large international cohorts across cultural settings, including promotion of patients’ rights in the context of research participation and engagement. This will focus on key issues including the role of ethics committees, data security regulations, patients’ rights, patient treatment settings including open or closed wards, public involvement in research design and grant development. Ultimately, the aspiration is to promote a unique perspective and experience of open science and data sharing sets a standard for a global health framework.

Acknowledgments Open Access funding provided by Projekt DEAL.

Author contributions Wrote the paper: SL, AH. Revised: SL, SM, AH and RJD. Critical feedback to the paper: XZ, JZ.

Funding This research was funded by the Berlin University Alliance (to SL), by Stiftung Charité (a BIH Visiting Professorship to RJD) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project-ID 402170461—TRR 265 to AH.

Compliance with ethical standards

Conflict of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
References

1. Allodi F, Dukszta J (1978) Psychiatric services in china: or, mao versus freud. SAGE Publications Sage, Los Angeles, CA

2. Amadio J, Bi G-Q, Boshears PF, Carter A, Devor A, Doya K, Garden H, Illes J, Johnson LSM, Jorgenson L (2018) Neuroethics questions to guide ethical research in the international brain initiatives. Neuron 100:19–36

3. World Medical Association (2013) World medical association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310:2191–2194

4. Bundesärztekammer ZEbd (2013) Zwangsbehandlung bei psychischen erkrankungen. Deutsches Arzteblatt 110:A1334–1338

5. Chen H, Phillips MR, Cheng H, Chen Q, Chen X, Fralick D, Zhang Y, Liu M, Huang J, Bueber M (2012) Mental health law of the People’s Republic of China (english translation with annotations): translated and annotated version of China’s new mental health law. Shanghai Arch Psy 24:305

6. Cibis M-L, Wackerhagen C, Müller S, Lang UE, Schmidt Y, Heinz A (2017) Vergleichbare betrachtung von aggressivität, zwangsmedikation und entweichungs raten zwischen offener und geschlossener tü rpolitik auf einer akutstation. Psychiatr Prax 44:141–147

7. Council E (1997) Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine. Convention on human rights and biomedicine. Conseil Eur Oviedo 16:44

8. Deutsche Gesellschaft für Psychiatrie und Psychotherapie PuNesdd (2014) Respect for self-determination and use of coercion in the treatment of mentally ill persons: an ethical position statement of the DGPPN. Der Nervenarzt 85:1419–1431

9. Dimitri G, Giacco D, Bauer M, Bird VJ, Greenberg L, Lasalvia A, Lorant V, Moskalewicz J, Nicaise P, Pfennig A (2018) Predictors of length of stay in psychiatric inpatient units: Does their effect vary across countries? European Psychiatry 48:6–12

10. Ferrari A (2008) Is it all about human nature? Ethical challenges of converging technologies beyond a polarized debate. Innov Eur J Soc Sci Res 21:1–24

11. Frances M, Rödder S, Weingart P (2007) Fraud: causes and culprits as perceived by science and the media. EMBO Rep 8:3–7

12. Gallagher B, Berman AH, Bieganski J, Jones AD, Foca L, Rai kes B, Schiratzi J, Urban M, Ullman S (2016) National human research ethics: a preliminary comparative case study of Germany, Great Britain, Romania, and Sweden. Ethics Behav 26:586–606

13. Gather J, Henkning T, Nossek A, Vollmann J (2017) Beneficial coercion in psychiatry?. Foundations and challenges, Mentis, Münster

14. Gerlinger G, Deister A, Heinz A, Koller M, Müller S, Steinitz T, Pollmächer T (2019) Nach der reform ist vor der reform. Der Nervenarzt 109:45–57

15. Guan J (2019) Artificial intelligence in healthcare and medicine: promises, ethical challenges and governance. Chin Med Sci J 34:76–83

16. Haglund K, von Essen L (2005) Locked entrance doors at psychiatric wards—advantages and disadvantages according to voluntarily admitted patients. Nord J Psychiatry 59:511–515

17. Heinz A, Kiefer F, Smolka MN, Endrass T, Beste C, Beck A, Liu S, Genua C, Romund L, Banaszewski T (2019) Addiction research consortium: Losing and regaining control over drug intake (recode)—from trajectories to mechanisms and interventions. Addict Biol 1:e12866

18. Heinz A, Zhao X, Liu S (2019) Implications of the association of social exclusion with mental health. JAMA psychiatry 6:245–345

19. Holmström I, Röing M (2010) The relation between patient-centeredness and patient empowerment: a discussion on concepts. Patient Educ Couns 79:167–172

20. Huber CG, Schneeberger AR, Kowalinski E, Fröhlich D, von Felten S, Walter M, Zinkler M, Beine K, Heinz A, Borgwardt S (2016) Suicide risk and absconding in psychiatric hospitals with and without open door policies: A 15 year, observational study. The Lancet Psychiatry 3:842–849

21. Jungfer H-A, Schneeberger AR, Borgwardt S, Walter M, Vogel M, Gaing KR, Lang UE, Huber CG (2014) Reduction of seclusion on a hospital-wide level: successful implementation of a less restrictive policy. J Psychiatr Res 54:94–99

22. Kalaji J, Otto I, Vollmann J, Juckel G, Gather J (2018) Requirements for the implementation of open door policies in acute psychiatry from a mental health professionals’ and patients’ view: a qualitative interview study. BMC psychiatry 18:304

23. Kiddle B, Inkster B, Prabhu G, Moutoussis M, Whitaker KJ, Bullmore ET, Dolan RJ, Fonagy P, Goodyer IM, Jones PB (2018) Cohort profile: The NSPEN 2400 cohort: A developmental sample supporting the welcome trust neuroscience in psychiatry network. Int J Epidemiol 47:18–19

24. Ma H, Shao Y (2019) Commentary: the implementation of china’s mental health law-defined risk criteria for involuntary admission: a national cross-sectional study of involuntary hospitalized patients. Front Psyg 10:121

25. Msoroka MS, Amundsen D (2018) One size fits not quite all: Universal research ethics with diversity. Res Ethics 14:1–17

26. Müller S, Walter H, Heinz A (2012) Zwangsbehandlungen bei psychisch kranken: Fixieren statt behandeln? Deutsches Arzteblatt 109:1A–198/B-174/C-17498

27. Müller S, Walter H, Kunze H, Konrad N, Heinz A (2012) Zwangsbehandlungen unter rechtsunsicherheit. Teil 2: Die aktuelle rechtsslage zu zwangsbehandlungen einwilligungsunfähiger patienten mit psychischen erkrankungen. Der Nervenarzt 83:1142–1149

28. Müller S, Walter H, Kunze H, Konrad N, Heinz A (2012) Zwangsbehandlungen unter rechtsunsicherheit. Teil 1: Die aktuelle rechtsslage zu zwangsbehandlungen einwilligungsunfähiger Patienten mit psychischen Erkrankungen. Der Nervenarzt 83:1150–1155

29. International ethical guidelines for health-related research involving humans (2016) Geneva. Council for International Organizations of Medical Sciences, Switzerland

30. Paus T (2020) Population neuroscience in addiction research; In Cognition and addiction. Elsevier, London

31. Pernot-Leplay E (2020) China’s approach on data privacy law: a third way between the US and the EU? Penn St J Law InternaT Aff 8:9

32. Poo M-m, Du J-l, Ip NY, Xiong Z-Q, Xu B, Tan T (2016) China brain project: Basic neuroscience, brain diseases, and brain-inspired computing. Neuron 92:591–596

33. Quinlan EB, Banaszewski T, Barker GI, Bokde AL, Bromberg U, Büchel C, DesrivèES S, Flor H, Frouin V, Garavan H (2019) Identifying biological markers for improved precision medicine in psychiatry. Mol Psych 1:11

34. Racine E, Dubljević V, Jox RJ, Baertschi B, Christensen JF, Farrisco M, Jotterand F, Kahane G, Müller S (2017) Can neuroscience
contribute to practical ethics? A critical review and discussion of the methodological and translational challenges of the neuroscience of ethics. Bioethics 31:328–337
36. Rittmannsberger H, Sartorius N, Brad M, Burtea V, Capraru N, Cernak P, Derovček M, Dobrin I, Frater R, Hasto J (2004) Changing aspects of psychiatric inpatient treatment. Eur Psychiatry 19:483–488
37. Roco MC, Bainbridge WS (2013) Converging technologies for improving human performance: Nanotechnology, biotechnology, information technology and cognitive science. Springer Sci Business Med 8:435–567
38. Sacristán JA, Aguirón A, Avendaño-Solá C, Garrido P, Carrión J, Gutiérrez A, Kroes R, Flores A (2016) Patient involvement in clinical research: Why, when, and how. Pat Prefer Adher 10:631
39. Schumann G, Benegal V, Yu C, Tao S, Jernigan T, Heinz A, Araya R, Yu L, Calhoun V (2019) Precision medicine and global mental health. Lancet Global Health 7:e32
40. Schumann G, Loth E, Banaschewski T, Barbot A, Barker G, Büchel C, Conrod P, Dalley J, Flor H, Gallinat J (2010) The image study: Reinforcement-related behaviour in normal brain function and psychopathology. Mole Psychiatry 15:1128–1139
41. Shi J, Tang L, Jing L, Geng J, Liu R, Luo L, Chen N, Liu Q, Gong X, Bo X (2019) Disparities in mental health care utilization among inpatients in various types of health institutions: a cross-sectional study based on ehr data in Shanghai. China BMC Public Health 19:1023
42. Shi S (2019) What will the development of psychiatry in China be in 10 years? General Psychiatry 32:e100025
43. Steinert T, Schreiber L, Metzger FG, Hirsch S (2019) Open doors in psychiatric hospitals: an overview of empirical findings. Der Nervenarzt 90:680–689
44. Thomas DR, Pastrana S, Hutchings A, Clayton R, Beresford AR (2017) Ethical issues in research using datasets of illicit origin. In: Proceedings of the 2017 Internet Measurement Conference, London, UK, November 1–3, 2017, p 18. https://conferences.sigcomm.org/imc/2017/papers/imc17-final1137.pdf. Accessed 27 July 2020
45. van der Merwe M, Bowers L, Jones J, Simpson A, Haglund K (2009) Locked doors in acute inpatient psychiatry: a literature review. J Psychiatr Ment Health Nurs 16:293–299
46. van Staden C (2007) Can involuntarily admitted patients give informed consent to participation in research? South African J Psychiatry 13:10–12
47. Wang G, Ma S (2016) The ethical challenges of converging technologies and their solutions. Chin Sci Bull 61:1632–1639
48. Wang Y, Yin J, Wang G, Li P, Bi G, Li S, Xia X, Song J, Pei G, Zheng JC (2019) Responsibility and sustainability in brain science, technology, and neuroethics in China—a culture-oriented perspective. Neuron 101:375–379
49. Wu B-J, Liao H-Y, Chen H-K, Lan T-H (2016) Psychopathology, psychopharmacological properties, decision-making capacity to consent to clinical research and the willingness to participate among long-term hospitalized patients with schizophrenia. Psychiatry Res 237:323–330
50. Zhang X, Zhang W, Zhao Y (2016) The Chinese ethical review system and its compliance mechanisms. https://trust-project.eu/wp-content/uploads/2016/03/Chinese-Ethics-Review-System.pdf. Accessed 27 July 2020
51. Zhao X (2017) Chinas erstes gesetz zur psychischen gesundheit 2013. Der Nervenarzt 88:500–509
52. Zhao X, Liu L, Hu C, Chen F, Sun X (2017) Necessity and feasibility of improving mental health services in China: a systematic qualitative review. Internat J Health Plan Manage 32:363–371
53. Zhou P, Xue D, Wang T, Tang Z, Zhang S, Wang J, Mao P, Xi Y, Wu R, Shi R (2009) Survey on the function, structure and operation of hospital ethics committees in Shanghai. J Med Ethics 35:512–516
54. Zhou W, Yu Y, Zhao X, Xiao S, Chen L (2019) Evaluating china’s mental health policy on local-level promotion and implementation: a case study of liuyang municipality. BMC Public Health 19:24
55. Zhou Z, Poo M-m (2018) Ethics in pace with scientific progress. Nat Sci Rev 5:299–299
56. Zielasek J, Gaebel W (2015) Mental health law in Germany. BJPsych Internat 12:14–16